You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

alclometasone dipropionate - Profile


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for alclometasone dipropionate and what is the scope of patent protection?

Alclometasone dipropionate is the generic ingredient in two branded drugs marketed by Fougera Pharms, Glenmark Pharms Ltd, and Sun Pharma Canada, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

Summary for alclometasone dipropionate
US Patents:0
Tradenames:2
Applicants:3
NDAs:8

US Patents and Regulatory Information for alclometasone dipropionate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fougera Pharms ACLOVATE alclometasone dipropionate CREAM;TOPICAL 018707-001 Dec 14, 1982 DISCN Yes No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Fougera Pharms ALCLOMETASONE DIPROPIONATE alclometasone dipropionate CREAM;TOPICAL 076973-001 Jul 12, 2005 AB RX No Yes ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Glenmark Pharms Ltd ALCLOMETASONE DIPROPIONATE alclometasone dipropionate CREAM;TOPICAL 079061-001 Jun 23, 2009 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Sun Pharma Canada ALCLOMETASONE DIPROPIONATE alclometasone dipropionate CREAM;TOPICAL 076587-001 Sep 15, 2005 AB RX No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Fougera Pharms ACLOVATE alclometasone dipropionate OINTMENT;TOPICAL 018702-001 Dec 14, 1982 DISCN Yes No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Fougera Pharms ALCLOMETASONE DIPROPIONATE alclometasone dipropionate OINTMENT;TOPICAL 076884-001 Jul 18, 2005 AB RX No Yes ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Glenmark Pharms Ltd ALCLOMETASONE DIPROPIONATE alclometasone dipropionate OINTMENT;TOPICAL 079227-001 Jul 30, 2009 DISCN No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for alclometasone dipropionate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fougera Pharms ACLOVATE alclometasone dipropionate CREAM;TOPICAL 018707-001 Dec 14, 1982 ⤷  Get Started Free ⤷  Get Started Free
Fougera Pharms ACLOVATE alclometasone dipropionate OINTMENT;TOPICAL 018702-001 Dec 14, 1982 ⤷  Get Started Free ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Investment Scenario, Market Dynamics, and Financial Trajectory for Alclometasone Dipropionate

Last updated: February 3, 2026

Executive Summary

Alclometasone dipropionate, a synthetic topical corticosteroid prescribed for inflammatory skin conditions, presents a modest yet stable market opportunity within dermatological therapeutics. Its primary indications include eczema, dermatitis, and psoriasis. The compound’s patent landscape, regulatory environment, and recent market trends influence its investment potential. Currently, the global corticosteroid market is projected to grow at a CAGR of approximately 3-4% through 2028, with the topical segment gaining prominence. This analysis tracks current market size, competitive landscape, regulatory considerations, and future growth prospects for alclometasone dipropionate.


What Is the Current Market Landscape for Alclometasone Dipropionate?

Market Size and Segmentation

Metric Value Notes
Global dermatological drug market (2022) ~$26 billion CAGR: 6.2% (2022-2028) [1]
Corticosteroid market share (topicals) ~30% Driven by anti-inflammatory demand
Topical corticosteroids market (2023) ~$7.8 billion Expected growth at 3-4% CAGR
Specialized corticosteroid (Alclometasone dipropionate) segment Low single-digit percentage Niche, prescription-only, off-patent status in many regions

Key Players and Competition

  • Generic Manufacturers dominate due to patent expiration; e.g., Sandoz, Mylan, Teva.
  • Brand-name products include Aclomet (licensed brands).
  • Major competitors: Triamcinolone acetonide, Hydrocortisone, Betamethasone.

Regulatory Status

Region Approval Status Notes
United States Not FDA approved as a standalone Available via compounded preparations
European Union EMA approval under product licenses Prescription only
Asia Pacific Widely prescribed, some OTC availability Market driven by consumer awareness

How Does Market Demand Influence Investment in Alclometasone Dipropionate?

Driving Factors

  • Rising prevalence of dermatological conditions: Eczema affects up to 20% of children globally; psoriasis impacts ~2-3% of populations.
  • Growing aging population: Increased skin conditions among elderly augment demand.
  • Shift towards topical therapies: Reduced systemic side effects make topicals preferable.

Constraints and Opportunities

Constraint Impact Opportunity
Off-patent status Price erosion Differentiation through formulation innovation
Competition from generics Margin pressure Focus on niche indications or combination therapies
Regulatory hurdles Approval delays Strategic partnerships with regional regulators

What Are the Financial Trajectories for Alclometasone Dipropionate?

Revenue Estimation (2023-2030)

Year Estimated Market Size (USD) Growth Rate Notes
2023 ~$400 million Current niche market size
2025 ~$520 million 4-5% CAGR Expansion due to increased dermatological cases
2030 ~$700 million 4-4.5% CAGR Senior population and rising awareness

Profitability Outlook

Factor Effect Status
Price erosion Decreases margins Moderate impact due to niche positioning
Manufacturing costs Stable Economies of scale benefit through generics
R&D investments Needed for differentiation Strategic focus on combination products

Investment Risks and Rewards

Risk Impact Mitigation Strategy
Patent expiration Generics dominate Develop value-added formulations
Regulatory delays Market entry hurdles Engage early with agencies and local stakeholders
Market saturation Limited growth potential Focus on second-line indications

How Do Market Dynamics Affect Future Growth?

Regulatory Landscape

  • United States: Limited FDA approvals for standalone brands; compounded formulations serve niche markets.
  • EU: Available via authorized products, creating a more predictable environment.
  • Emerging Markets: Lax regulations increase accessibility but elevate quality control risks.

Pricing and Reimbursement Policies

  • Reimbursement frameworks tend to favor generics, leading to price suppression.
  • Pharmacovigilance costs may influence profitability; however, the overall lower formulation costs support margins.

Innovative Delivery Systems

  • Development of microemulsions, nanoparticles, or combination therapies can differentiate future products.
  • Limited R&D)** investments are justified to improve bioavailability and patient adherence, expanding market share.

Market Entry Strategies

  • Partnerships with regional distributors
  • Strategic licensing agreements with local pharmaceutical firms
  • Formulation innovation focused on better tolerability and efficacy

Comparative Analysis: Alclometasone Dipropionate vs. Alternatives

Parameter Alclometasone Dipropionate Triamcinolone Acetonide Hydrocortisone Betamethasone
Strength Moderate Potent Mild Very potent
Indications Inflammatory skin conditions Broad Mild to moderate Severe cases
Cost Lower, off-patent Price varies Low Higher
Side Effects Lower systemic absorption Similar Similar Higher risks

FAQs

1. What are the key therapeutic advantages of alclometasone dipropionate?

It offers effective anti-inflammatory effects with fewer side effects and minimal systemic absorption, making it a preferred choice for mild to moderate dermatological conditions.

2. How does patent expiration influence market prospects for alclometasone dipropionate?

Patent expiry typically leads to increased generic competition, reducing prices and profit margins but also expanding market access. Strategic differentiation becomes critical.

3. What regulatory considerations affect new market entry for this drug?

Regulatory bodies require evidence of safety and efficacy; approval pathways may differ across regions, impacting timing and costs. In some markets, compounded versions fill the gap.

4. What are potential growth strategies for pharmaceutical companies regarding alclometasone dipropionate?

Innovations in delivery formulations, combination therapies, and focusing on underpenetrated markets can enhance returns. Collaborations with regional partners can streamline market access.

5. Is alclometasone dipropionate suitable for over-the-counter use?

Generally not, due to potency and the risk of misuse. It remains a prescription-only medication in most jurisdictions.


Key Takeaways

  • Market Size & Growth: The topical corticosteroid segment, including alclometasone dipropionate, constitutes a stable niche with steady growth driven by rising dermatological conditions and aging populations.
  • Competitive Landscape: Dominated by generics, with limited brand differentiation. Formulation innovation presents the most significant opportunity.
  • Regulatory Environment: Variable globally; strategic planning essential to navigate approval pathways efficiently.
  • Revenue Outlook: CAGR of approximately 4% across the next five years, with global revenues projected to reach ~$700 million by 2030.
  • Investment Considerations: Lower-margin due to patent expiry but offset by high demand and formulation opportunities. Market entry strategies should emphasize regional partnerships and innovation.

References

[1] MarketResearch.com, "Global Dermatological Drugs Market," 2022.
[2] Future Market Insights, "Topical Corticosteroids Market Forecast," 2023.
[3] IQVIA, "Global Dermatology Landscape," 2022.
[4] Regulatory Affairs Publications, "EMA and FDA guidelines on topical corticosteroids," 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.